Beta Drugs Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 21, 2024, 2:47 am

Market Cap	1,980 Cr.
Current Price	2,060
High / Low	2,326/1,060
Stock P/E	48.3
Book Value	188
Dividend Yield	0.00 %
ROCE	32.8 %
ROE	26.0 %
Face Value	10.0
PEG Ratio	1.55

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for

Competitors of

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Gujarat Themis Biosyn Ltd	3,354 Cr.	308	390/128	63.6	20.5	0.22 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	62.6 Cr.	84.4	94.9/26.6	24.0	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.9 Cr.	24.5	24.5/8.74	46.6	6.64	0.00 %	2.65 %	2.08 %	10.0
Godavari Drugs Ltd	86.7 Cr.	115	155/87.0	13.0	55.4	0.00 %	14.4 %	15.5 %	10.0
Glenmark Life Sciences Ltd	12,416 Cr.	1,013	1,335/645	29.3	207	2.22 %	28.1 %	21.1 %	2.00
Industry Average	19,016.52 Cr	1,181.31		56.05	186.30	0.32%	16.20%	16.32%	6.27

All Competitor Stocks of

Quarterly Result

Month	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024
Sales	47	44	51	65	88	96	112	115	141	154
Expenses	37	36	41	51	68	73	86	88	108	127
Operating Profit	9	8	11	14	20	23	27	26	33	27
OPM %	20%	19%	21%	22%	23%	24%	24%	23%	23%	18%
Other Income	0	0	0	0	0	0	0	0	1	1
Interest	1	2	1	1	1	1	1	1	1	1
Depreciation	2	2	3	4	3	4	5	6	5	4
Profit before tax	7	5	7	9	16	18	21	20	27	22
Tax %	27%	14%	21%	30%	28%	27%	25%	25%	25%	25%
Net Profit	5	4	5	7	12	13	16	15	20	17
EPS in Rs	5.33	4.46	5.39	6.80	12.22	13.61	16.47	15.48	20.67	17.23

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Sales	51	66	91	116	184	227	296
Expenses	41	54	73	91	141	174	236
Operating Profit	9	12	18	25	43	53	60
OPM %	19%	18%	20%	21%	23%	23%	20%
Other Income	0	0	0	0	1	1	1
Interest	1	1	3	2	2	2	3
Depreciation	2	3	4	7	7	10	10
Profit before tax	7	8	12	16	34	41	49
Tax %	1%	-2%	21%	27%	28%	25%	25%
Net Profit	7	8	9	12	25	31	36
EPS in Rs	7.82	9.30	9.80	12.19	25.83	31.95	37.90
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	14.29%	12.50%	33.33%	108.33%	24.00%	16.13%
Change in YoY Net Profit Growth (%)	0.00%	-1.79%	20.83%	75.00%	-84.33%	-7.87%

has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	35%
3 Years:	37%
TTM:	31%

Compounded Profit Growth
10 Years:	%
5 Years:	35%
3 Years:	46%
TTM:	18%

Stock Price CAGR
10 Years:	%
5 Years:	92%
3 Years:	55%
1 Year:	38%

Return on Equity
10 Years:	%
5 Years:	26%
3 Years:	28%
Last Year:	26%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:36 am

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	9	9	10	10	10	10	10	10
Reserves	24	32	48	59	83	113	148	171
Borrowings	8	20	23	17	21	20	15	19
Other Liabilities	9	22	28	31	45	55	82	95
Total Liabilities	50	83	107	118	158	198	254	295
Fixed Assets	13	18	44	40	55	63	65	66
CWIP	1	15	0	3	0	0	0	0
Investments	0	0	0	1	1	1	0	0
Other Assets	35	50	63	74	102	135	190	229
Total Assets	50	83	107	118	158	198	254	295

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	17	0	8	19	30	23	31
Cash from Investing Activity +	-11	-21	-15	-6	-22	-19	-14
Cash from Financing Activity +	5	12	9	-8	-1	-2	-7
Net Cash Flow	12	-9	2	5	7	2	9

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	1.00	-8.00	-5.00	8.00	22.00	33.00	45.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor Days	104	139	128	106	90	101
Inventory Days	37	104	102	100	87	106
Days Payable	81	143	119	127	123	139
Cash Conversion Cycle	60	100	111	79	53	68
Working Capital Days	75	100	95	88	70	88
ROCE %		18%	21%	22%	36%	34%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	66.68%	66.71%	66.71%	66.71%	66.71%	66.71%	66.73%	66.73%	66.73%	66.73%	66.73%	66.73%
FIIs	0.00%	0.00%	0.00%	0.00%	0.29%	0.29%	0.29%	0.29%	0.32%	0.32%	0.32%	0.90%
DIIs	0.28%	0.29%	0.29%	0.29%	0.04%	0.04%	0.04%	0.04%	0.02%	0.02%	0.06%	0.12%
Public	33.03%	33.01%	33.00%	33.00%	32.96%	32.96%	32.94%	32.93%	32.93%	32.92%	32.87%	32.25%
No. of Shareholders	542	675	762	1,296	1,407	1,444	1,424	1,451	1,722	1,928	2,116	2,323

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	37.90	31.95	25.82	12.20	9.93
Diluted EPS (Rs.)	37.90	31.95	25.82	12.20	9.93
Cash EPS (Rs.)	48.08	42.78	33.37	19.34	13.70
Book Value[Excl.RevalReserv]/Share (Rs.)	163.43	127.82	96.05	71.37	59.41
Book Value[Incl.RevalReserv]/Share (Rs.)	163.43	127.82	96.05	71.37	59.41
Revenue From Operations / Share (Rs.)	307.59	236.24	191.22	120.79	94.45
PBDIT / Share (Rs.)	63.82	56.05	45.20	26.26	19.05
PBIT / Share (Rs.)	53.65	45.22	37.65	19.11	15.14
PBT / Share (Rs.)	50.71	42.70	35.68	16.59	12.45
Net Profit / Share (Rs.)	37.90	31.95	25.82	12.20	9.79
NP After MI And SOA / Share (Rs.)	37.90	31.95	25.82	12.20	9.79
PBDIT Margin (%)	20.74	23.72	23.63	21.73	20.17
PBIT Margin (%)	17.44	19.14	19.69	15.81	16.03
PBT Margin (%)	16.48	18.07	18.65	13.73	13.18
Net Profit Margin (%)	12.32	13.52	13.50	10.09	10.36
NP After MI And SOA Margin (%)	12.32	13.52	13.50	10.09	10.36
Return on Networth / Equity (%)	23.19	24.99	26.88	17.08	16.48
Return on Capital Employeed (%)	30.43	32.10	33.24	22.09	20.65
Return On Assets (%)	14.33	15.48	15.72	9.97	8.78
Long Term Debt / Equity (X)	0.03	0.05	0.12	0.16	0.17
Total Debt / Equity (X)	0.06	0.13	0.17	0.21	0.34
Asset Turnover Ratio (%)	1.31	1.27	1.09	0.82	0.79
Current Ratio (X)	2.10	2.03	1.98	1.99	1.53
Quick Ratio (X)	1.51	1.54	1.52	1.53	1.19
Inventory Turnover Ratio (X)	4.17	4.16	5.70	4.47	4.43
Interest Coverage Ratio (X)	21.76	22.31	22.88	10.43	7.08
Interest Coverage Ratio (Post Tax) (X)	13.92	13.72	14.07	5.85	4.64
Enterprise Value (Cr.)	1168.47	599.62	542.92	119.61	52.99
EV / Net Operating Revenue (X)	3.95	2.64	2.95	1.03	0.58
EV / EBITDA (X)	19.04	11.13	12.49	4.74	2.89
MarketCap / Net Operating Revenue (X)	4.01	2.65	2.96	0.99	0.42
Price / BV (X)	7.55	4.90	5.89	1.68	0.67
Price / Net Operating Revenue (X)	4.01	2.65	2.96	0.99	0.42
EarningsYield	0.03	0.05	0.04	0.10	0.24

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of as of December 22, 2024 is: 2,408.12

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 22, 2024, is Undervalued by 16.90% compared to the current share price 2,060.00

Intrinsic Value of as of December 22, 2024 is: 3,156.17

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 22, 2024, is Undervalued by 53.21% compared to the current share price 2,060.00

Last 5 Year EPS CAGR: 31.06%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 18.71%, which is a positive sign. The company has higher reserves (84.75 cr) compared to borrowings (17.88 cr), indicating strong financial stability. The company has shown consistent growth in sales (147.29 cr) and profit (23.86 cr) over the years.	The stock has a high average Working Capital Days of 73.71, which may not be favorable. The stock has a high average Cash Conversion Cycle of 67.29, which may not be favorable.

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in :
1. Net Profit Margin: 12.32%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 30.43% (Industry Average ROCE: 16.2%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 23.19% (Industry Average ROE: 16.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 13.92
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.51
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 48.3 (Industry average Stock P/E: 56.05)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.06
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 124.85 Cr. and Equity Capital is Rs. 9.61 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Village Nandpur, Baddi Himachal Pradesh 174101	cs@betadrugslimited.com http://www.betadrugslimited.com

Management
Name	Position Held
Mr. Rahul Batra	Chairperson & Managing Director
Mr. Varun Batra	Joint Managing Director
Mrs. Seema Chopra	Whole Time Director
Mr. Balwant Singh	Whole Time Director
Mr. Manmohan Khanna	Independent Director
Mr. Ashutosh Shukla	Whole Time Director
Mr. Rohit Parti	Independent Director

FAQ

What is the latest intrinsic value of ?

The latest intrinsic value of as on 21 December 2024 is ₹2408.12, which is 16.90% higher than the current market price of ₹2,060.00. The stock has a market capitalization of 1,980 Cr. and recorded a high/low of 2,326/1,060 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹171 Cr and total liabilities of ₹295 Cr.

What is the Market Cap of ?

The Market Cap of is 1,980 Cr..

What is the current Stock Price of as on 21 December 2024?

The current stock price of as on 21 December 2024 is 2,060.

What is the High / Low of stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of stocks is 2,326/1,060.

What is the Stock P/E of ?

The Stock P/E of is 48.3.

What is the Book Value of ?

The Book Value of is 188.

What is the Dividend Yield of ?

The Dividend Yield of is 0.00 %.

What is the ROCE of ?

The ROCE of is 32.8 %.

What is the ROE of ?

The ROE of is 26.0 %.

What is the Face Value of ?

The Face Value of is 10.0.

Share Price and Basic Stock Data

Stock P/E, Current Price, and Intrinsic Value Over Time

Competitors of

Quarterly Result

Quarterly Chart

Profit & Loss - Annual Report

Profit & Loss Yearly Chart

YoY Net Profit Growth

Growth

Balance Sheet

Reserves and Borrowings Chart

Cash Flow

Free Cash Flow

Free Cash Flow Chart

Financial Efficiency Indicators

Financial Efficiency Indicators Chart

Share Holding Pattern

Shareholding Pattern Chart

No. of Shareholders

ROCE Trend

EPS Trend

Key Financial Ratios

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Strength and Weakness

About the Company - Qualitative Analysis

FAQ

What is the latest intrinsic value of ?

What is the Market Cap of ?

What is the current Stock Price of as on 21 December 2024?

What is the High / Low of stocks in FY 2024-2025?

What is the Stock P/E of ?

What is the Book Value of ?

What is the Dividend Yield of ?

What is the ROCE of ?

What is the ROE of ?

What is the Face Value of ?

About the Author

Getaka